View Financial HealthCantourage Group 배당 및 자사주 매입배당 기준 점검 0/6Cantourage Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 14Cantourage Group SE, Annual General Meeting, Jun 24, 2026Cantourage Group SE, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.공시 • Mar 27Cantourage Group SE to Report Fiscal Year 2025 Results on May 15, 2026Cantourage Group SE announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on May 15, 2026Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.분석 기사 • Dec 24An Intrinsic Calculation For Cantourage Group SE (ETR:HIGH) Suggests It's 32% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €4.98 Cantourage Group...New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€45.6m market cap, or US$53.5m).분석 기사 • Sep 09Cantourage Group SE's (ETR:HIGH) Intrinsic Value Is Potentially 56% Above Its Share PriceKey Insights The projected fair value for Cantourage Group is €5.51 based on 2 Stage Free Cash Flow to Equity...Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.공시 • May 19Cantourage Group SE, Annual General Meeting, Jun 25, 2025Cantourage Group SE, Annual General Meeting, Jun 25, 2025, at 13:00 W. Europe Standard Time.New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Market cap is less than US$100m (€55.5m market cap, or US$60.8m).공시 • Mar 09Cantourage Group SE to Report First Half, 2025 Results on Oct 31, 2025Cantourage Group SE announced that they will report first half, 2025 results on Oct 31, 2025Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.Price Target Changed • Jul 18Price target increased by 10% to €11.00Up from €10.00, the current price target is provided by 1 analyst. New target price is 59% above last closing price of €6.90. Stock is down 36% over the past year.공시 • May 17Cantourage Group SE, Annual General Meeting, Jun 26, 2024Cantourage Group SE, Annual General Meeting, Jun 26, 2024, at 13:00 W. Europe Standard Time.New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change).분석 기사 • Jan 05Calculating The Intrinsic Value Of Cantourage Group SE (ETR:HIGH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €6.86 Cantourage...New Risk • Dec 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€92.4m market cap, or US$99.9m).New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).공시 • Jul 22Cantourage Group SE Provides Earnings Guidance for the Fiscal Year 2023Cantourage Group SE provided earnings guidance for the fiscal year 2023. For the year, the company expects sales growth to be in the higher double-digit percentage range compared to the previous year.New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 HIGH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: HIGH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cantourage Group 배당 수익률 vs 시장HIGH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (HIGH)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (HIGH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HIGH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HIGH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HIGH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: HIGH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 20:09종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cantourage Group SE는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ellis AcklinFirst Berlin Equity Research GmbHTim KruseMontega AGIngo SchmidtMontega AG1명의 분석가 더 보기
공시 • May 14Cantourage Group SE, Annual General Meeting, Jun 24, 2026Cantourage Group SE, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
공시 • Mar 27Cantourage Group SE to Report Fiscal Year 2025 Results on May 15, 2026Cantourage Group SE announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on May 15, 2026
Price Target Changed • Mar 09Price target increased by 9.1% to €9.00Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year.
분석 기사 • Dec 24An Intrinsic Calculation For Cantourage Group SE (ETR:HIGH) Suggests It's 32% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €4.98 Cantourage Group...
New Risk • Sep 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€45.6m market cap, or US$53.5m).
분석 기사 • Sep 09Cantourage Group SE's (ETR:HIGH) Intrinsic Value Is Potentially 56% Above Its Share PriceKey Insights The projected fair value for Cantourage Group is €5.51 based on 2 Stage Free Cash Flow to Equity...
Major Estimate Revision • Sep 08Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week.
Price Target Changed • Sep 06Price target decreased by 18% to €10.25Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year.
공시 • May 19Cantourage Group SE, Annual General Meeting, Jun 25, 2025Cantourage Group SE, Annual General Meeting, Jun 25, 2025, at 13:00 W. Europe Standard Time.
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Market cap is less than US$100m (€55.5m market cap, or US$60.8m).
공시 • Mar 09Cantourage Group SE to Report First Half, 2025 Results on Oct 31, 2025Cantourage Group SE announced that they will report first half, 2025 results on Oct 31, 2025
Major Estimate Revision • Jan 29Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week.
Major Estimate Revision • Jan 21Consensus estimates of losses per share improve by 75%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week.
Price Target Changed • Dec 05Price target increased by 7.5% to €10.75Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year.
Price Target Changed • Jul 18Price target increased by 10% to €11.00Up from €10.00, the current price target is provided by 1 analyst. New target price is 59% above last closing price of €6.90. Stock is down 36% over the past year.
공시 • May 17Cantourage Group SE, Annual General Meeting, Jun 26, 2024Cantourage Group SE, Annual General Meeting, Jun 26, 2024, at 13:00 W. Europe Standard Time.
New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).
New Risk • Feb 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change).
분석 기사 • Jan 05Calculating The Intrinsic Value Of Cantourage Group SE (ETR:HIGH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Cantourage Group fair value estimate is €6.86 Cantourage...
New Risk • Dec 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€92.4m market cap, or US$99.9m).
New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
공시 • Jul 22Cantourage Group SE Provides Earnings Guidance for the Fiscal Year 2023Cantourage Group SE provided earnings guidance for the fiscal year 2023. For the year, the company expects sales growth to be in the higher double-digit percentage range compared to the previous year.
New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).